GlassScriptPhysician profile
David R Parker
NPI 1194740597
$1,991.72
in general payments reported to CMS, 2019-2025
25 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $386 · 2021: $199 · 2024: $282 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $559.25 | 2024-2025 | Proclaim |
| Allergan, INC. | $160.94 | 2019-2020 | |
| Corcept Therapeutics | $139.89 | 2021-2024 | Korlym |
| Amgen INC. | $132.63 | 2019-2020 | |
| Novo Nordisk INC | $106.95 | 2019-2021 | |
| Orexo US, INC. | $101.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $99.97 | 2020-2021 | |
| Alkermes, INC. | $98.58 | 2019 | |
| Lilly USA, LLC | $84.94 | 2019-2021 | |
| Indivior INC. | $78.45 | 2019 | |
| Vertiflex, INC. | $69.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.62 | 2019-2020 | |
| Si-Bone, INC. | $50.77 | 2019 | |
| Glaxosmithkline, LLC. | $38.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $31.68 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.35 | 2019 | |
| Shionogi INC | $21.60 | 2019 | |
| Eisai INC. | $21.59 | 2021 | |
| Esperion Therapeutics, INC. | $18.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.95 | 2019 | |
| Sanofi Pasteur INC. | $15.89 | 2019 | |
| Merck Sharp & Dohme LLC | $14.23 | 2019 | |
| Mdd US Operations, LLC | $13.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.